Literature DB >> 211182

Infection of mouse liver by human adenovirus type 5.

S J Duncan, F C Gordon, D W Gregory, J L McPhie, R Postlethwaite, R White, H N Willcox.   

Abstract

CBA mice, inoculated intravenously with large doses of adenovirus type 5, showed raised levels of serum aspartate aminotransferase (SAAT; EC 2.6.I.I) and died within a few days from histologically demonstrable hepatic necrosis. After inoculation of I LD50, virus was rapidly taken up by the tissues where infectivity then declined greatly. Organ titres then increased about 100-fold by 48 h p.i. but, in the liver, which showed intranuclear inclusion bodies, and by electron microscopy, scattered intranuclear and intracytoplasmic adenovirions, the increase was 10000- to 100000-fold. P antigen was detected by single radial diffusion in liver extracts, and by immunofluorescence in 80% of liver cells at 36 h p.i. Hexon, penton base and fibre antigens appeared later and in fewer cells. The maximum amount of hexon, of demonstrable type 5 specificity, was shown by radioimmunoassay to be equivalent to up to 5 x 1011 whole adenovirions/g liver. It is concluded that human adenovirus type 5 undergoes an abortive but lytic infection in most liver cells but that replication may proceed to completion in a few.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 211182     DOI: 10.1099/0022-1317-40-1-45

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  42 in total

Review 1.  The promise and potential hazards of adenovirus gene therapy.

Authors:  L S Young; V Mautner
Journal:  Gut       Date:  2001-05       Impact factor: 23.059

2.  E1A and E1B proteins inhibit inflammation induced by adenovirus.

Authors:  Jerome Schaack; Michael L Bennett; Jeff D Colbert; Andres Vazquez Torres; Gerald H Clayton; David Ornelles; John Moorhead
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-19       Impact factor: 11.205

3.  Costimulatory protein B7-1 enhances the cytotoxic T cell response and antibody response to hepatitis B surface antigen.

Authors:  X S He; H S Chen; K Chu; M Rivkina; W S Robinson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

4.  Adenovirus infection triggers a rapid, MyD88-regulated transcriptome response critical to acute-phase and adaptive immune responses in vivo.

Authors:  Zachary C Hartman; Anne Kiang; Ruth S Everett; Delila Serra; Xiao Y Yang; Timothy M Clay; Andrea Amalfitano
Journal:  J Virol       Date:  2006-11-22       Impact factor: 5.103

5.  Productive replication of human adenovirus type 5 in canine cells.

Authors:  Vladimir V Ternovoi; Long P Le; Natalya Belousova; Bruce F Smith; Gene P Siegal; David T Curiel
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

6.  Replication properties of human adenovirus in vivo and in cultures of primary cells from different animal species.

Authors:  Christian Jogler; Dennis Hoffmann; Dirk Theegarten; Thomas Grunwald; Klaus Uberla; Oliver Wildner
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

7.  A new hamster model for adenoviral vaccination.

Authors:  R N Hjorth; G M Bonde; W A Pierzchala; S K Vernon; F P Wiener; M H Levner; M D Lubeck; P P Hung
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

8.  IIIa deleted adenovirus as a single-cycle genome replicating vector.

Authors:  Catherine M Crosby; Michael A Barry
Journal:  Virology       Date:  2014-07-02       Impact factor: 3.616

9.  Use of tissue-specific microRNA to control pathology of wild-type adenovirus without attenuation of its ability to kill cancer cells.

Authors:  Ryan Cawood; Hannah H Chen; Fionnadh Carroll; Miriam Bazan-Peregrino; Nico van Rooijen; Leonard W Seymour
Journal:  PLoS Pathog       Date:  2009-05-22       Impact factor: 6.823

10.  Evaluation of cross-reactive cell-mediated immune responses among human, bovine and porcine adenoviruses.

Authors:  A Sharma; M Tandon; Y S Ahi; D S Bangari; R Vemulapalli; S K Mittal
Journal:  Gene Ther       Date:  2010-02-18       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.